.png?#)
KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’
KalVista Pharmaceuticals said Friday that the FDA pushed back its decision on whether to approve its on-demand oral drug for hereditary angioedema, citing “heavy workload and limited resources” at the agency. KalVista had expected the ...
KalVista Pharmaceuticals said Friday that the FDA pushed back its decision on whether to approve its on-demand oral drug for hereditary angioedema, citing “heavy workload and limited resources” at the agency.
KalVista had expected the ...
